In melanoma, afatinib was tested and, as gefitinib and lapatinib, it showed minimal cytotoxic activity alone but was more effective when combined with AKT inhibitors in vemurafenib resistant BRAF mutated melanoma (Table 6) [122]. Here, BRAF is linked to melanoma.